CKD (TSE:6407) Following Embezzlement Arrest, Does Its Valuation Still Hold Up?

CKD (TSE:6407) is in focus after disclosing that a former accounting staff member at subsidiary CKD GLOBAL SERVICE CORP. was arrested for embezzling ¥178 million, which was fully booked in the latest fiscal year.

See our latest analysis for CKD.

Despite the embezzlement headline, CKD’s recent 30 day share price return of 16.8% and year to date share price return of 127.72% indicate strong momentum. The 1 year total shareholder return of 184.55% highlights how reinvested dividends have added to gains.

If this kind of strong run has you thinking about where else the market is rewarding growth stories, it could be worth scanning 30 robotics and automation stocks

After CKD’s sharp re rating, powered by strong recent returns and set against the embezzlement shock being accounted for, does the current price still offer an attractive trade off between risk and potential reward as valuation comes into focus?

Price-to-Earnings of 35.6x: Is It Justified For CKD?

On a P/E of 35.6x, CKD is priced well above much of the Machinery sector, even after the recent share price surge and the embezzlement issue being accounted for.

The P/E multiple compares the current share price to earnings per share. It effectively shows how much investors are paying today for each unit of current earnings. For a company like CKD, which operates in automation machinery and components, a higher P/E can reflect expectations for steadier growth and profit resilience compared with more cyclical peers.

Relative to peers, CKD trades at a lower P/E than the peer average of 39.5x, which suggests the market is not assigning the very highest earnings premium to the stock. However, compared with the broader JP Machinery industry average of 14.5x and an estimated fair P/E of 24.8x, the current 35.6x looks significantly richer. This implies the market is already pricing in stronger earnings progress than both the sector average and the level the SWS fair ratio suggests the valuation could move toward.

Explore the SWS fair ratio for CKD

Result: Price-to-Earnings of 35.6x (OVERVALUED)

However, CKD’s story still carries risk, including the governance questions raised by the embezzlement case and the possibility that current earnings may not support such a high P/E ratio.

Find out about the key risks to this CKD narrative.

Another View: What Our DCF Model Says About CKD

The SWS DCF model points in the opposite direction to the P/E story for CKD, with an estimated future cash flow value of ¥3,391.83 versus the current ¥7,230 share price. That gap suggests investors are paying a steep premium to today’s cash flow assumptions, so what might justify it?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CKD for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 19 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If CKD’s mixed signals leave you unsure, move quickly from headline impressions to the underlying data. Then decide what feels reasonable for your portfolio, starting with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CKD?

If CKD has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target potential mispricings by reviewing companies screened as 19 high quality undervalued stocks based on their fundamentals and current market pricing.
• Strengthen your income focus by checking out businesses flagged as 43 dividend fortresses with yields that may suit long term payout goals.
• Prioritise resilience by running through stocks highlighted in the 52 resilient stocks with low risk scores that emphasise sturdier financial and risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com